PMV Pharmaceuticals’ Updated Rezatapopt Data Puts Precision Oncology Back in Focus
PMV Pharmaceuticals’ updated PYNNACLE Phase 2 data gives investors a closer look at rezatapopt and its TP53 Y220C precision-oncology strategy.
Savara Shares Slip After FDA Delays Autoimmune PAP Decision
Savara’s missed FDA target date leaves investors facing a longer wait for clarity on its autoimmune …
Revolution Medicines Rallies on Clinical Data as Biotech Decouples From Weak Market
Revolution Medicines showed premarket relative strength as clinical data offset a 1.0% S&P 500 decli…
Capricor Therapeutics Defies Market Selloff as Traders Position for FDA Catalyst
CAPR rallied in premarket trading as the Nasdaq and S&P 500 declined, putting the biotech’s FDA cata…
Alnylam’s $25 Million Regeneron Milestone Puts Its RNAi Model in Focus
Alnylam’s $25 million Livsayis milestone highlights the commercial value of its RNAi platform and pa…
Black Diamond Gains as FDA Maps Accelerated-Approval Path for Silevertinib
FDA guidance on accelerated approval and a broad EGFR mutation definition may reduce uncertainty aro…
J&J Seeks FDA Approval to Expand CAPLYTA Into Bipolar Mania
J&J’s CAPLYTA filing could create a fifth potential indication, broadening its psychiatric franchise…
ADC Therapeutics Pitches Zynlonta Expansion as a Commercial Growth Driver
ADC Therapeutics is emphasizing Zynlonta’s market opportunity and broader commercial availability as…
Merck Maps Out Its Post-Keytruda Growth Strategy With Nine New Medicines
Merck is positioning nine newer medicines and vaccines, including intismeran, as part of its strateg…
Regeneron Buy Rating Reaffirmed After Fresh FDA Approval
Truist reiterated its Buy rating on $REGN after a new FDA approval, giving traders a concrete cataly…